Aytu biopharma receives a 180-day extension by nasdaq to regain compliance with bid price rule

Englewood, co / accesswire / november 22, 2022 / aytu biopharma, inc. (the "company" or "aytu") (nasdaq:aytu), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the company received written notification from the listing qualifications department of the nasdaq stock market, llc ("nasdaq"), granting the company's request for a 180-day extension to regain compliance with nasdaq's minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the "bid price rule"). the company has until may 22, 2023 to meet the requirement.
AYTU Ratings Summary
AYTU Quant Ranking